Surgery Partners, Inc. (SGRY) is a leading healthcare services company in the United States. SGRY operates a nationwide network of surgical centers and hospitals that are dedicated to providing high-quality, low-cost outpatient care. The company prides themselves on putting patients first and making healthcare more accessible and affordable for all.
Surgery Partners, headquartered in Nashville, Tennessee, operates more than 180 locations, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices, and ancillary care services. The company's portfolio also includes a variety of facilities that focus on orthopedics, ophthalmology, gastroenterology, pain management and more.
Established in 2004, Surgery Partners has grown significantly, not just organically, but also through strategic acquisitions. The company's key growth strategy is to increase its service offerings and geographical footprint through partnerships with physicians and health systems.
The company operates under a unique model which distinguishes it from other healthcare service providers. By partnering directly with physicians, Surgery Partners bolsters the quality of care, improves patient outcomes and enhances the overall patient experience. Physicians play a vital role in the company's service delivery, administrative decision-making, and strategic planning, thus creating a highly cooperative and effective framework.
Surgery Partners also takes pride in leveraging technology to optimize patient care. The company continuously invests in advanced medical equipment and innovative technologies that enable more effective diagnosis and treatment of diseases as well as better patient monitoring and recovery.
The company's commitment to delivering superior surgical services, coupled with its focus on patient safety and satisfaction, has helped SGRY earn an excellent reputation. That said, like many healthcare providers, the company also faces significant challenges, including regulatory changes, cost containment pressures, and the need to continually improve quality and efficiency.
Despite these challenges, Surgery Partners is well-positioned for future growth. As the healthcare landscape continues to evolve, SGRY's focus on patient-centric care, the surgeon partnership model, the adoption of new technologies, and robust business strategies are expected to keep the company on a growth trajectory. SGRY is undoubtedly redefining outpatient care by transforming how surgical services are delivered.
In conclusion, Surgery Partners, Inc. distinguishes itself with its commitment to providing high-quality, cost-effective outpatient surgical services. By focusing on partnerships with surgeons, implementing innovative technologies, and sticking to patient-centric principles, they've managed to establish themselves as a leading healthcare service company in the nation.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Surgery Partners (SGRY) revised its 2026 revenue outlook to $3.08 billion to $3.18 billion, attributing the change to the removal of Idaho Falls Facilities' contribution. This update follows significant share price declines, with the stock down 7.86% in the past week and 13.17% year-to-date, raising questions about its valuation. Despite the pressure, the company is seen as undervalued by some analysts who highlight its strong position in the outpatient surgical procedures market.
Surgery Partners announced the completion of the sale of its ownership interests in its Idaho Falls facilities to Intermountain Health for $797 million in gross proceeds. This transaction streamlines Surgery Partners' business to focus on short-stay surgical services and is expected to improve its balance sheet leverage and free cash flow conversion. The company also updated its 2026 financial guidance to reflect the impact of the sale.
JP Morgan has maintained a Neutral rating on Surgery Partners (SGRY) but raised its price target to $15.00 from $14.00, reflecting cautious optimism despite the stock being 42.1% undervalued by GF Value™. The company has a GF Score™ of 61/100, with concerns regarding financial strength and profitability, but shows positive momentum and recent insider buying. Investors are advised to proceed with caution due to the company's unprofitability and cash-flow challenges.
Surgery Partners Director Teresa DeLuca purchased 11,250 shares of the company's common stock on August 18, 2026, increasing her direct equity stake by 20%. This transaction, valued at $161,213, signals insider confidence despite the company's stock price slumping 37.6% over the past 12 months and its significant debt. Analysts generally remain bullish on Surgery Partners, with a median one-year price target of $19.
Teresa Deluca, a director at Surgery Partners Inc (SGRY), recently purchased 10,000 shares at $14.35 each, increasing her total holdings to 66,843 shares and signaling confidence in the company. Despite this insider buying, the stock is classified as a "Possible Value Trap" by GuruFocus, trading significantly below its intrinsic value, which suggests investors should exercise caution. The mixed insider activity and balanced guru ownership indicate a cautious but not entirely negative outlook for the surgical services provider.
Surgery Partners, Inc. director Teresa DeLuca purchased 10,000 shares of the company's common stock at a weighted average price of $14.35 per share on August 18, 2026. This transaction, revealed in a Form 4 filing on August 19, 2026, increases her direct beneficial ownership to 66,843 common shares. The filing indicates a commitment by DeLuca to provide detailed pricing information upon request.
Surgery Partners (SGRY) reported Q2 2026 earnings, highlighting revenue of $848.9 million and Adjusted EBITDA of $125.2 million, driven by high-acuity surgical growth. The company announced the significant divestiture of its Idaho Falls market for $795 million to focus on a pure-play short-stay surgical model, aiming to simplify operations and reduce debt. Despite missing the annual M&A investment target, Surgery Partners reaffirmed its full-year 2026 guidance and emphasized its strategy of organic growth, de novo development, and disciplined capital allocation.
Surgery Partners (SGRY) reported Q2 2026 results with higher sales but wider losses, alongside a slower-than-planned M&A pace as it focuses on portfolio optimization. Despite reaffirming revenue guidance, the company's disciplined but slower acquisition strategy, combined with rising interest costs, poses questions about its ability to achieve profitability targets and support its investment case around scale in ambulatory surgery centers. Investors are encouraged to assess how smaller tuck-in deals and divestitures will impact future earnings.
Surgery Partners (SGRY) reported Q2 2026 earnings, highlighting revenue of $848.9 million and Adjusted EBITDA of $125.2 million. The company announced the significant divestiture of its Idaho Falls market for $795 million, aiming to streamline operations, reduce debt, and focus on its core short-stay surgical model. Despite missing its M&A investment target for 2026, the company reaffirmed its full-year guidance and emphasized growth through high-acuity procedures, physician recruitment, and de novo development.